Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
16/7/20
Potential Investigator-Led Clinical Collaborations
Guy's and St Thomas' NHS Foundation Trust
"We are working with patient groups to plan a grant application for a Phase II clinical trial programme on SFX-01 in children with ASD, hoping to recruit from a consortium of UK hospitals.
Our interest, and that of the parents of some children with ASD, was first triggered when a small clinical study showed that sulforaphane helped improve quality of life in autistic young people.
Our end goal is improving the range of treatment options available for autistic young people, in order to improve quality of life and independence.
” Dr Michael Absoud, a consultantin paediatric neurodisability"We are delighted that Evgenwill support our plans to undertake a clinical trial on SFX-01 in patients with NASH. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology.
University of Dundee
”John Dillon,Professor of Hepatology and Gastrenterology, University of Dundee's the School of Medicine "We are pleased that Evgen will support our plans to undertake a clinical trial on SFX-01 in patients with CKD.
University of Rochester- New York
Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing.’’ Thu Le, Professor of Medicine and Chief of the Division of Nephrology at the University of Rochester Medical Center, New York.
Cheers viable, SFX-01 is in evaluation for multiple disease targets, including breast cancer in collaboration with Manchester University where phase 2 results were outstanding and life changing for some patients, and is now in the process of planned phase 2b trials. Gl ;-)
Rob Clarke
@RobClarkeLab
Read about my group's talented postdocs and their brilliant achievements here!
Manchester Cancer Research Centre@MCRCnews
· Sep 22
To celebrate our valued postdocs, we wanted to recognise their incredible scientific achievements over the past year that are helping to beat cancer.
Read their success in our blog here: hxxp://mcrc.manchester.ac.uk/Blog/post/postdoc-appreciation-week-mcrc-postdoc-publications
- Written by @GeorginaBinnie (1/3)
Postdoc Appreciation Week - MCRC Postdoc Publications
22/09/2020
Postdoc Appreciation Week 2020 (21st – 25th September) is an annual event designed to highlight the global achievements and contributions of postdocs (research fellows, research associates, bioinformatic officers etc.). Originating with the National Postdoc Association in the USA (National Postdoc Appreciation Week), the University of Manchester has since won the 2019 Elsevier ‘Best New Event’ Award for Postdoc Appreciation Week and is now part of the first UK/ROI-wide consortium celebrating postdocs across UK and Irish Universities.
2019–20 peer-reviewed publications from postdocs include Dr Rachel Eyre, Dr Angélica Santiago-Gómez and Dr Bruno Simões’ co-authorship of multiple, cutting-edge articles, including:
‘Increased expression of interleukin-1 receptor characterises anti-estrogen resistant ALDH+ breast cancer stem cells’ (Santiago-Gómez, Eyre and Simões [senior author] et al.)
‘Targeting STAT3 signalling using stabilised sulforaphane (SFX-01) inhibits endocrine resistant stem-like cells in ER-positive breast cancer’ (Simões [first Author], Santiago-Gómez, Eyre et al.). Dr on the first and first author on the latter paper
‘Microenvironmental IL1ß promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling’ (Eyre [first author], Santiago-Gómez, Simões et al.)
‘PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer’ (Santiago-Gómez [first author], Simões et al)
Dr Hannah Harrison has contributed to multiple peer-reviewed papers, including as co-first author of ‘A role for CBFß in maintaining the metastatic phenotype of breast cancer cells’ and a co-author of ‘Hypoxia-induced secretion stimulates breast cancer stem cell regulatory signalling pathways’.
http://www.mcrc.manchester.ac.uk/Blog/post/postdoc-appreciation-week-mcrc-postdoc-publications
@ 16:14 plus many more
MM - You are obviously a dedicated follower and student of EVG. I am considering another biotech, besides continuing with SCLP, where I have been invested for 10+ years. SFX-1 looks more than just interesting. I'll give it close scrutiny.
SFX-01's Covid-19 patient trials dated to start 1/10/20.
BBC News -Scotland recorded 486 new positive coronavirus tests which represented the biggest single day's number since mass testing began.
https://www.bbc.co.uk/news/uk-scotland-scotland-politics-54265540
Scottish numbers: 24 September 2020
465 new cases of COVID-19 reported; this is 7.9% of newly tested individuals.
2 new reported death(s) of people who have tested positive.
10 people were in intensive care yesterday with recently confirmed COVID-19.
84 people were in hospital with recently confirmed COVID-19.
15,362 new tests for COVID-19 that reported results.